Drug Profile

Imarikiren - Scohia Pharma

Alternative Names: SCO-272; TAK-272

Latest Information Update: 05 Nov 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Takeda
Class Antihypertensives; Benzimidazoles; Morpholines
Mechanism of Action Renin inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase II Diabetic nephropathies; Hypertension

Most Recent Events

01 Feb 2022 Imarikiren - Scohia Pharma is available for licensing as of 01 Feb 2022. https://www.scohia.com/eng/sys/pipeline/ (Scohia Pharma pipeline, February 2022)
29 Jan 2018 Chemical structure information added
19 Jan 2018 Imarikiren is still at phase II development stage for Diabetic nephropathies (Early-stage disease) in Japan (PO) (Scohia Pharma pipeline, January 2018)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com